Table 1.
Exacerbation discovery cohort: demographics (n = 59)
| Male, n (%) | 33 (56%) |
| Age (yr) | 31.3 (10.2) |
| Severe CFTR genotype (class I-III) | 46 (78%) |
| Baseline FEV1 (% predicted) | 59.1 (27.0) |
| Baseline FEV1 (L) | 2.1 (1.0) |
| Weight (kg) | 63.1 (12.7) |
| BMI (kg/m2) | 22.3 (3.7) |
| CF related diabetes | 19 (32%) |
| CF liver disease | 9 (15%) |
| CFTR modulator use | 11 (18.6%) |
| Frequent exacerbation (⩾2) in preceding year | 30 (51%) |
| Chronic Pseudomonas aeruginosa | 40 (68%) |
| Chronic MSSA | 20 (33%) |
| Viral infection detected (any method) | 18 (32%) |
Definition of abbreviations: BMI = body mass index; CF = cystic fibrosis; CFTR = cystic fibrosis transmembrane conductance regulator; FEV1 = forced expiratory volume in 1 second; MSSA = methicillin-sensitive Staphylococcus aureus.
Mean (standard deviation) unless otherwise stated. Lung function and BMI are at baseline.